Background: Chronic Obstructive Pulmonary Disease (COPD) has become the third leading cause of death worldwide. Moreover, COPD is also a major cause of decreased quality of life in patients, with a significant morbidity rate. Without proper prevention and treatment efforts, COPD can become a global health economic burden due to high mortality and morbidity rates. Vitamin D is known as one of the antioxidant micronutrients that can prevent molecular damage and potentially halt the progression of COPD, as indicated by a decrease in Malondialdehyde (MDA). However, the role of high-dose vitamin D in maintaining stable COPD levels, specifically its impact on plasma MDA levels, is still unknown. Methods: The participants in the study were COPD patients with GOLD 2 and GOLD 3 classifications, those who routinely took bronchodilator medication, and those whose 25(OH)D levels were less than 32 ng/ml. Patients were instructed to take 1000 IU of vitamin D orally for three months. We used paired T-tests to look at vitamin D and MDA levels. Results: The study found that administering 1000 IU of vitamin D supplements for three months significantly increased and decreased MDA levels (p<0.05). Conclusion: In patients with stable COPD, high-dose vitamin D can inhibit oxidative stress and function as an antioxidant.